We’re on a mission to make early liver cancer detection as routine as a cholesterol test.
Every year, over 30,000 Americans die from liver cancer. The majority of those deaths were potentially preventable — not because we lack treatment options, but because the cancers were found too late to treat.
MoleculeDx was founded to close this gap. We combined next-generation genomic sequencing with clinical-grade AI to create a blood test that’s simple enough for any at-risk patient to use, accurate enough for physicians to trust, and affordable enough for widespread adoption.
Our Fusion-detect™ platform doesn’t just screen — it catches cancers at the stage when treatment can still save lives.
When liver cells become cancerous, they produce characteristic fusion gene events — chromosomal rearrangements that generate novel protein sequences. These are detectable in the blood years before a tumor is visible on imaging.
Our test identifies specific chromosomal fusion events in circulating tumor DNA — a molecular fingerprint that is highly specific to hepatocellular carcinoma.
Our Fusion-detect™ AI is trained on 50,000+ clinical samples. It classifies results with 96.7% accuracy, removing the subjectivity that plagues many diagnostic tests.
All samples are processed in our CLIA-certified laboratory under strict federal standards. Every result is reviewed by a licensed clinical pathologist before release.
Former Director of Genomics at NIH. 20+ years in cancer biomarker development and early detection technology.
Serial health-tech entrepreneur. Previously led operations at two oncology diagnostics companies through FDA clearance.
Hepatologist and clinical researcher. Collaborated with UPMC on liver cancer surveillance protocols for 12 years.
© 2024 MoleculeDx Inc. All rights reserved.
This test is not a substitute for medical diagnosis. Consult your physician with all results.
